Trial Profile
An Investigation of the Antidepressant Effects of an NMDA Antagonist in Treatment-Resistant Major Depression.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Lanicemine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 24 Jan 2012 Actual patient no 22 added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Actual patient no 22 added as reported by ClinicalTrials.gov.
- 24 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.